Furthermore, the CXCR4 antagonists suppressed the growth of lung cancer growth: Peptide R prevented the recruitment of metastasis-initiating cells and inflammatory monocytes toward CXCL12-enriched sites (69) and AMD3100 reduced the progression of cancer in orthotopic SCLC mouse model (155). This evidence concerns the gene CXCR4 and cancer.